130 related articles for article (PubMed ID: 2507265)
1. Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects.
Riddle MC; Hart JS; Bouma DJ; Phillipson BE; Youker G
Diabetes Care; 1989 Oct; 12(9):623-9. PubMed ID: 2507265
[TBL] [Abstract][Full Text] [Related]
2. Comparison of combined therapies in treatment of secondary failure to glyburide.
Trischitta V; Italia S; Mazzarino S; Buscema M; Rabuazzo AM; Sangiorgio L; Squatrito S; Vigneri R
Diabetes Care; 1992 Apr; 15(4):539-42. PubMed ID: 1499473
[TBL] [Abstract][Full Text] [Related]
3. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM.
Groop LC; Widén E; Ekstrand A; Saloranta C; Franssila-Kallunki A; Schalin-Jäntti C; Eriksson JG
Diabetes Care; 1992 Jul; 15(7):831-4. PubMed ID: 1516500
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE
Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
[TBL] [Abstract][Full Text] [Related]
5. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
[TBL] [Abstract][Full Text] [Related]
6. Bed time NPH-insulin plus combined sulfonylurea-biguanide oral therapy for treating refractory non insulin dependent diabetic patients.
di Cianni G; Benzi L; Ciccarone AM; Cecchetti P; Navalesi R
Diabete Metab; 1992; 18(6):468-9. PubMed ID: 1297606
[No Abstract] [Full Text] [Related]
7. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.
Riddle M; Hart J; Bingham P; Garrison C; McDaniel P
Am J Med Sci; 1992 Mar; 303(3):151-6. PubMed ID: 1595776
[TBL] [Abstract][Full Text] [Related]
8. Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes.
Miller JL; Salman K; Shulman LH; Rose LI
Clin Pharmacol Ther; 1993 Mar; 53(3):380-4. PubMed ID: 8453858
[TBL] [Abstract][Full Text] [Related]
9. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
10. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
11. Concomitant insulin and sulfonylurea therapy in patients with type II diabetes. Effects on glucoregulation and lipid metabolism.
Osei K; O'Dorisio TM; Falko JM
Am J Med; 1984 Dec; 77(6):1002-9. PubMed ID: 6439036
[TBL] [Abstract][Full Text] [Related]
12. Effects of combined insulin-sulfonylurea therapy in type II patients.
Lewitt MS; Yu VK; Rennie GC; Carter JN; Marel GM; Yue DK; Hooper MJ
Diabetes Care; 1989 Jun; 12(6):379-83. PubMed ID: 2499443
[TBL] [Abstract][Full Text] [Related]
13. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
Ahmed AB; Home PD
Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
[TBL] [Abstract][Full Text] [Related]
14. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Clauson P; Karlander S; Steen L; Efendic S
Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
[TBL] [Abstract][Full Text] [Related]
15. Comparison of morning or bedtime insulin with and without glyburide in secondary sulfonylurea failure.
Soneru IL; Agrawal L; Murphy JC; Lawrence AM; Abraira C
Diabetes Care; 1993 Jun; 16(6):896-901. PubMed ID: 8325203
[TBL] [Abstract][Full Text] [Related]
16. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T
Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290
[TBL] [Abstract][Full Text] [Related]
17. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study.
Nathan DM; Roussell A; Godine JE
Ann Intern Med; 1988 Mar; 108(3):334-40. PubMed ID: 3124685
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of the efficiency of ultralente insulin and NPH insulin combined with sulfonylurea in type 2 diabetes patients with secondary tolerance to sulfonylurea. Possible selection criteria].
Sangiorgio L; Rabuazzo MA; Cordaro G; Grasso G; Condorelli L; Lunetta M
Minerva Endocrinol; 1996 Jun; 21(2):47-52. PubMed ID: 9026680
[TBL] [Abstract][Full Text] [Related]
19. Treatment of type I diabetes with a combination of glyburide and insulin.
Gums JG; Curry RW; Montes de Oca G; Skluth HA; Reynolds LR
Ann Pharmacother; 1992 Jun; 26(6):757-62. PubMed ID: 1611155
[TBL] [Abstract][Full Text] [Related]
20. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
